Skip to main content
Top
Published in: Cellular Oncology 6/2014

01-12-2014 | Original Paper

E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells

Authors: Akhilesh Rawat, Gopal Gopisetty, Rajkumar Thangarajan

Published in: Cellular Oncology | Issue 6/2014

Login to get access

Abstract

Purpose

We and others show that SOSTDC1 is down-regulated in breast cancer tissues compared to matched normal tissues. Previously, we found that epigenetic mechanisms underlie the down-regulation of SOSTDC1 in gastric cancer cells. The aim of this study was to assess the putative epigenetic regulation of SOSTDC1 expression in breast cancer cells.

Methods

Microarray-based expression profiling was performed in a series of primary breast cancers and matched normal tissues. Real-time PCR was performed to assess SOSTDC1 and E4BP4 mRNA levels in MCF7, BT549, MBMDA231, T47D (breast cancer) and HEK293T (normal kidney) cell lines. Methylation-specific PCR (MSP) and bisulfite sequencing PCR (BSP) were performed to assess the methylation level of the SOSTDC1 gene promoter, and 5-Aza 2-deoxycytidine (5'-Aza-dC) treatment was used to induce its demethylation. A luciferase assay was used to measure SOSTDC1 promoter activity in vitro. Stable shRNA-mediated knockdown of E4BP4 was carried out in MCF7 cells and confirmed by Western blotting. Finally, MCF7 cell proliferation and survival were measured by MTS assay.

Results

We found that SOSTDC1 is frequently down-regulated in primary breast cancers (98.2 %) and in all breast cancer cell lines tested. MSP and BSP analyses revealed SOSTC1 promoter hypermethylation at CpG sites. 5'-Aza-dC treatment induced a striking down-regulation of SOSTDC1 gene expression, whereas BSP analysis showed demethylation of its promoter. Subsequent in silico SOSTDC1 promoter analysis indicated the presence of putative transcriptional repressor E4BP4 binding sites, and promoter deletion studies indeed revealed repressor binding regions encompassing these E4BP4 binding sites. Relative quantification of E4BP4 expression showed an inverse correlation to SOSTDC1 expression in the breast cancer cell lines tested. Exogenous over-expression of E4BP4 in HEK-293 and BT549 cells reduced SOSTDC1 expression and its promoter activity, respectively. Stable shRNA-mediated E4BP4 BT549 and MCF7 knock-down cells treated with 5'-Aza-dC exhibited up-regulation of SOSTDC1 expression and a concomitant inhibition of cell proliferation and survival.

Conclusion

From our results we conclude that the transcriptional repressor E4BP4 plays a role in repressing epigenetically regulated SOSTDC1 expression in breast cancer cells, which can be reverted by E4BP4 silencing.
Literature
1.
go back to reference S. Tabarestani, S.M. Ghaderian, H. Rezvani, R. Mirfakhraie, A. Ebrahimi, H. Attarian, J. Rafat, M. Ghadyani, H.A. Alavi, N. Kamalian, A. Rakhsha, E. Azargashb, Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. Cell. Oncol. 37, 107–118 (2014)CrossRef S. Tabarestani, S.M. Ghaderian, H. Rezvani, R. Mirfakhraie, A. Ebrahimi, H. Attarian, J. Rafat, M. Ghadyani, H.A. Alavi, N. Kamalian, A. Rakhsha, E. Azargashb, Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. Cell. Oncol. 37, 107–118 (2014)CrossRef
2.
go back to reference A. Rawat, G. Gopal, G. Selvaluxmy, T. Rajkumar, Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. Cell. Oncol. 36, 459–67 (2013)CrossRef A. Rawat, G. Gopal, G. Selvaluxmy, T. Rajkumar, Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. Cell. Oncol. 36, 459–67 (2013)CrossRef
3.
go back to reference A. Geurts van Kessel, The cancer genome: from structure to function. Cell. Oncol. 37, 155–165 (2014) A. Geurts van Kessel, The cancer genome: from structure to function. Cell. Oncol. 37, 155–165 (2014)
4.
go back to reference J.S. de Groot, X. Pan, J. Meeldijk, E. van der Wall, P.J. van Diest, C.B. Moelans, Validation of DNA promoter hypermethylation biomarkers in breast cancer–a short report. Cell. Oncol. 37, 297–303 (2014)CrossRef J.S. de Groot, X. Pan, J. Meeldijk, E. van der Wall, P.J. van Diest, C.B. Moelans, Validation of DNA promoter hypermethylation biomarkers in breast cancer–a short report. Cell. Oncol. 37, 297–303 (2014)CrossRef
5.
go back to reference E. Dulaimi, J. Hillinck, I. de Caceres Ibanez, T. Al-Saleem, P. Cairns, Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin. Cancer Res. 10, 6189–6193 (2004)PubMedCrossRef E. Dulaimi, J. Hillinck, I. de Caceres Ibanez, T. Al-Saleem, P. Cairns, Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin. Cancer Res. 10, 6189–6193 (2004)PubMedCrossRef
6.
go back to reference X. Yang, L. Yan, N.E. Davidson, DNA methylation in breast cancer. Endocr Relat Cancer. 8, 115–127 (2001)PubMedCrossRef X. Yang, L. Yan, N.E. Davidson, DNA methylation in breast cancer. Endocr Relat Cancer. 8, 115–127 (2001)PubMedCrossRef
7.
go back to reference T.X. Xiang, Y. Yuan, L. Li, Z.H. Wang, L.Y. Dan, G.S. Chen Ren, Q. Tao, Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer. 30, 12–20 (2013)CrossRef T.X. Xiang, Y. Yuan, L. Li, Z.H. Wang, L.Y. Dan, G.S. Chen Ren, Q. Tao, Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer. 30, 12–20 (2013)CrossRef
8.
go back to reference K.A. Clausen, K.R. Blish, C.E. Birse, M.A. Triplette, T.E. Kute, G.B. Russell, R.B. D’Agostino Jr., L.D. Miller, F.M. Torti, S.V. Torti, SOSTDC1 differentially modulates Smad and beta–catenin activation and is down–regulated in breast cancer. Breast Cancer Res. Treat. 129, 737–746 (2010)PubMedCentralPubMedCrossRef K.A. Clausen, K.R. Blish, C.E. Birse, M.A. Triplette, T.E. Kute, G.B. Russell, R.B. D’Agostino Jr., L.D. Miller, F.M. Torti, S.V. Torti, SOSTDC1 differentially modulates Smad and beta–catenin activation and is down–regulated in breast cancer. Breast Cancer Res. Treat. 129, 737–746 (2010)PubMedCentralPubMedCrossRef
9.
go back to reference K.R. Blish, W. Wang, W.M.C. Du, C.E. Birse et al., A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol. Biol. Cell 19, 457–464 (2008)PubMedCentralPubMedCrossRef K.R. Blish, W. Wang, W.M.C. Du, C.E. Birse et al., A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol. Biol. Cell 19, 457–464 (2008)PubMedCentralPubMedCrossRef
10.
go back to reference G. Gopal, U.M. Raja, S. Shirley, K.R. Rajalekshmi, T. Rajkumar, SOSTDC1 down-regulation of expression involves CpG methylation and is a potential prognostic marker in gastric cancer. Cancer Genet. 206, 174–182 (2013)PubMedCrossRef G. Gopal, U.M. Raja, S. Shirley, K.R. Rajalekshmi, T. Rajkumar, SOSTDC1 down-regulation of expression involves CpG methylation and is a potential prognostic marker in gastric cancer. Cancer Genet. 206, 174–182 (2013)PubMedCrossRef
11.
go back to reference I.G. Cowell, H.C. Hurst, Protein-protein interaction between the transcriptional repressor E4BP4 and the TBP-binding protein Dr1. Nucleic Acids Res. 24, 3607–3613 (1996)PubMedCentralPubMedCrossRef I.G. Cowell, H.C. Hurst, Protein-protein interaction between the transcriptional repressor E4BP4 and the TBP-binding protein Dr1. Nucleic Acids Res. 24, 3607–3613 (1996)PubMedCentralPubMedCrossRef
12.
go back to reference I.G. Cowell, A. Skinner, H.C. Hurst, Transcriptional repression by a novel member of the bZIP family of transcription factors. Mol. Cell. Biol. 12, 3070–3077 (1992)PubMedCentralPubMed I.G. Cowell, A. Skinner, H.C. Hurst, Transcriptional repression by a novel member of the bZIP family of transcription factors. Mol. Cell. Biol. 12, 3070–3077 (1992)PubMedCentralPubMed
13.
go back to reference T. Rajkumar, N. Vijayalakshmi, G. Gopal, K. Sabitha, S. Shirley, U.M. Raja, S.A. Ramakrishnan, Identification and validation of genes involved in gastric tumorigenesis. Cancer Cell Int. 10(45), 1475–2867 (2010). 10-45 T. Rajkumar, N. Vijayalakshmi, G. Gopal, K. Sabitha, S. Shirley, U.M. Raja, S.A. Ramakrishnan, Identification and validation of genes involved in gastric tumorigenesis. Cancer Cell Int. 10(45), 1475–2867 (2010). 10-45
14.
go back to reference S. Ammanamanchi, M.G. Brattain, Sp3 is a transcriptional repressor of transforming growth factor-beta receptors. J. Biol. Chem. 276, 3348–3352 (2001)PubMedCrossRef S. Ammanamanchi, M.G. Brattain, Sp3 is a transcriptional repressor of transforming growth factor-beta receptors. J. Biol. Chem. 276, 3348–3352 (2001)PubMedCrossRef
15.
go back to reference N.H. Nabilsi, R.R. Broaddus, D.S. Loose, DNA methylation inhibits p53-mediated survivin repression. Oncogene 28, 2046–2050 (2009)PubMedCrossRef N.H. Nabilsi, R.R. Broaddus, D.S. Loose, DNA methylation inhibits p53-mediated survivin repression. Oncogene 28, 2046–2050 (2009)PubMedCrossRef
16.
go back to reference I.G. Cowell, E4BP4/NFIL3, a PAR-related bZIP factor with many roles. Bioessays 24, 1023–1029 (2002)PubMedCrossRef I.G. Cowell, E4BP4/NFIL3, a PAR-related bZIP factor with many roles. Bioessays 24, 1023–1029 (2002)PubMedCrossRef
Metadata
Title
E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells
Authors
Akhilesh Rawat
Gopal Gopisetty
Rajkumar Thangarajan
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 6/2014
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-014-0204-6

Other articles of this Issue 6/2014

Cellular Oncology 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine